Efficacy of Pegylated Liposomal Doxorubicin in Low-Grade Serous Ovarian Carcinoma

Rose, Peter G.; Radeva, Milena; Michener, Chad M.; Link, Nicholas A.; Adbul-Karim, Fadi

doi:10.1097/igc.0000000000000977

Cited by 8 publications

(5 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Rose et al reported a complete response rate of 14.3%. The treatment of stable disease by PLD resulted in increased PFS in 78.6% of cases, by an average of 350% [ 89 ]. The addition of bevacizumab to chemotherapy for recurrent LGSC might enhance response rates.…”

Section: Managementmentioning

confidence: 99%

Low-Grade Serous Carcinoma of the Ovary: The Current Status

et al. 2022

View full text Add to dashboard Cite

Low-grade serous carcinoma (LGSC) of the ovary is a rare histological subtype of epithelial ovarian carcinoma. It has distinct clinical behavior and a specific molecular profile. Compared with high-grade serous carcinoma, this tumor presents at a younger age, has an indolent course, and is associated with prolonged survival. LGSC can arise de novo or originate following a serous borderline tumor (SBT). Pathological differentiation between LGSC and other ovarian carcinoma histological subtypes is fundamental. Several factors might influence the overall outcome, such as the age at diagnosis, current smoking, elevated body mass index, mutational status, hormonal receptors’ expression, and Ki-67 proliferation index. Surgery is the main treatment option in LGSC, and efforts must be maximized to achieve a microscopic residual in metastatic disease. Despite being relatively chemo-resistant, adjuvant platinum-based chemotherapy remains the standard of care in LGSC. Hormonal maintenance therapy after adjuvant chemotherapy results in improved outcomes. Treatment options for disease recurrence include secondary cytoreductive surgery, chemotherapy, hormonal therapy, targeted therapy, and clinical trials. Advancements in genomic studies and targeted therapies are expected to change the treatment landscape in LGSC.

show abstract

Section: Managementmentioning

confidence: 99%

Low-Grade Serous Carcinoma of the Ovary: The Current Status

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Median time to progression was 34.7 weeks (range: 4.3 – 232.4 weeks) for platinum-sensitive patients and 26.4 (range: 8.4 – 149 weeks) for platinum-resistant patients. Pegylated liposomal doxorubicin (PLD) seems to be the most active regimen for LGSOC 29 . There is no data which compares the different regimens for platinum-based therapy to treat LGSOC.…”

Section: Reviewmentioning

confidence: 99%

Low-grade Serous Ovarian Carcinoma

Ricciardi

Baert

Ataseven

et al. 2018

Geburtshilfe Frauenheilkd

View full text Add to dashboard Cite

In the early 2000s a two-tier grading system was introduced for serous ovarian cancer. Since then, we have increasingly come to accept that low-grade serous ovarian carcinoma (LGSOC) is a separate entity with a unique mutational landscape and clinical behaviour. As less than 10% of serous carcinomas of the ovary are low-grade, they are present in only a small number of patients in clinical trials for ovarian cancer. Therefore the current treatment of LGSOC is based on smaller trials, retrospective series, and subgroup analysis of large clinical trials on ovarian cancer. Surgery plays a major role in the treatment of patients with LGSOC. In the systemic treatment of LGSOC, hormonal treatment and targeted therapies seem to play an important role.

show abstract

“…[50] In vitro experimental studies have shown that LGSOC has strong resistance to paclitaxel, carboplatin, cisplatin, cyclophosphamide, and gemcitabine and weak resistance to etoposide, adriamycin, and topotecan. [49] Rose et al [51] evaluated 21 LGSOC patients with PLD application and found that 3 patients (14.3%) achieved CR after the application of PLD, 67% of the patients had stable disease, and the response rate to PLD was independent of platinum sensitivity. PLD showed good application prospects.…”

Section: Chemotherapymentioning

confidence: 99%

Advances in precision therapy of low-grade serous ovarian cancer: A review

Wang,

Cao,

et al. 2024

Medicine

View full text Add to dashboard Cite

Low-grade serous ovarian carcinoma (LGSOC) is a rare subtype of ovarian cancer that accounts for approximately 6% to 10% of serous ovarian cancers. The clinical treatment of LGSOC is similar to that of high-grade serous ovarian carcinoma, however, its clinical and molecular characteristics are different from those of high-grade serous ovarian carcinoma. This article reviews the research on gene diagnosis, surgical treatment, chemotherapy, and biological therapy of LGSOC, providing reference for clinical diagnosis and treatment of LGSOC. Surgery is the cornerstone of LGSOC treatment and maximum effort must be made to achieve R0 removal. Although LGSOC is not sensitive to chemotherapy, postoperative platinum-based combination chemotherapy remains the first-line treatment option for LGSOC. Additional clinical trials are needed to confirm the clinical benefits of chemotherapy and explore new chemotherapy protocols. Hormone and targeted therapies may also play important roles. Some patients, particularly those with residual lesions after treatment, may benefit from hormone maintenance therapy after chemotherapy. Targeted therapies, such as MEKi, show good application prospects and are expected to change the treatment pattern of LGSOC. Continuing to further study the genomics of LGSOC, identify its specific gene changes, and combine traditional treatment methods with precision targeted therapy based on second-generation sequencing may be the direction for LGSOC to overcome the treatment bottleneck. In future clinical work, comprehensive genetic testing should be carried out for LGSOC patients to accumulate data for future scientific research, in order to find more effective methods and drugs for the treatment of LGSOC.

show abstract

Efficacy of Pegylated Liposomal Doxorubicin in Low-Grade Serous Ovarian Carcinoma

Abstract: Pegylated liposomal doxorubicin is relatively active in LGSOC. The treatment of stable disease resulted in increase in PFS in 78.6% of patients by a mean of 350%.

Cited by 8 publications

References 17 publications

Low-Grade Serous Carcinoma of the Ovary: The Current Status

Low-Grade Serous Carcinoma of the Ovary: The Current Status

Low-grade Serous Ovarian Carcinoma

Advances in precision therapy of low-grade serous ovarian cancer: A review

Contact Info

Product

Resources

About